Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Hodgkin Disease × Vincristine × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

OTHER 23 NETWORK 9 NIH 7 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 26 Lymphoma, Follicular 17 Lymphoma, Non-Hodgkin 16 Lymphoma 12 Precursor Cell Lymphoblastic Leukemia-Lymphoma 11 Lymphoma, B-Cell 10 Neoplasms 8 Lymphoma, Mantle-Cell 7 Lymphoma, T-Cell, Peripheral 6 Recurrence 5 Leukemia 5 Hematologic Diseases 4 Sarcoma, Kaposi 3 Neuroblastoma 3 Lymphoma, B-Cell, Marginal Zone 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 HIV Infections 3 Acquired Immunodeficiency Syndrome 3 Wilms Tumor 2 Lymphoma, T-Cell 2 Lymphoma, Large-Cell, Anaplastic 2 Leukemia, Myeloid, Acute 2 Burkitt Lymphoma 2 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Oligodendroglioma 1 Neurocytoma 1 Neoplasms by Histologic Type 1

Interventions

Brentuximab Vedotin 20 pembrolizumab 11 Vinblastine 6 Doxorubicin 6 Dacarbazine 6 plerixafor 4 fludarabine 4 Nivolumab 4 Cyclophosphamide 4 Azacitidine 4 Melphalan 3 Granulocyte Colony-Stimulating Factor 3 Gemcitabine 3 Filgrastim 3 Etoposide 3 Busulfan 3 Bleomycin 3 pegfilgrastim 2 mocetinostat 2 givinostat hydrochloride 2 givinostat 2 fludarabine phosphate 2 cc-486 2 abexinostat 2 TPI-287 2 Panobinostat 2 Mycophenolic Acid 2 Leukapheresis 2 Clofarabine 2 Carmustine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03407144 2026-02-19

MK-3475-667

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡